• 500 Mg Conversion

500 Mg Conversion

There are 300 milligrams in 0.3 gram To convert any value in grams to milligrams, just multiply the value in grams by the conversion factor 1000. So, 0.3 gram times 1000 is equal to 300 mg.

UsesIn women, oral conjugated estrogens USP and synthetic conjugated estrogens A are used for the management of moderate to severe vasomotor symptoms associated with menopause and for the management of vulvar and vaginal atrophy (atrophic vaginitis). If estrogens are used solely for the management of vulvar and vaginal atrophy, use of topical vaginal preparations should be considered. Synthetic conjugated estrogens B is used for the management of moderate to severe vasomotor symptoms and for the management of severe vaginal dryness, pain with sexual intercourse, and symptoms of vulvar and vaginal atrophy associated with menopause. Oral conjugated estrogens USP also is used for the management of female hypoestrogenism secondary to hypogonadism, castration, or primary ovarian failure.Oral conjugated estrogens USP is used adjunctively with other therapeutic measures (e.g., diet, calcium, weight-bearing exercise including walking, running, physical therapy) to retard further bone loss and the progression of osteoporosis associated with estrogen deficiency in postmenopausal women.

1. Convert density: 0.3 mg/ml (milligram / milliliter) to other units. This is simple to use online converter of weights and measures. Simply select the input unit, enter the value and click 'Convert' button. The value will be converted to all other units of the actual measure. You can simply convert for example between metric, UK imperial and US customary units system.
2. Answers: One milligram (mg) is 1/1000 gram (g). To get your answer, simply divide x by 1,000. You can use the converters to find the answers to your questions. To do this, simply select the appropriate unit from each 'select' box above, enter your figure ( x) into the ' value to convert ' box and click the ' Convert!

While estrogen replacement therapy is effective for the prevention of osteoporosis in women and has been shown to reduce bone resorption and retard or halt bone loss in postmenopausal women, such therapy is associated with a number of adverse effects. If prevention of postmenopausal osteoporosis is the sole indication for therapy with oral conjugated estrogens, alternative therapy (e.g., alendronate, raloxifene, risedronate) should be considered.Another therapeutic option involves use of conjugated estrogens in combination with an estrogen agonist-antagonist (bazedoxifene) for the management of moderate to severe vasomotor symptoms associated with menopause and for prevention of osteoporosis. Dosage and Administration Reconstitution and AdministrationConjugated estrogens USP is usually administered orally, but may also be administered intravaginally or by deep IM or slow IV injection. Synthetic conjugated estrogens A and synthetic conjugated estrogens B are administered orally.When parenteral administration of conjugated estrogens USP is required, IV injection is preferred because of the more rapid response obtained following this route of administration compared to IM injection. For direct IV injection, the drug should be administered slowly to avoid the occurrence of a flushing reaction.For parenteral administration, conjugated estrogens USP powder for injection is reconstituted with 5 mL of sterile water for injection. Using aseptic technique, the diluent should then be slowly added, directing the flow against the inner wall of the vial (Secule), while gently agitating the container to facilitate dissolution of the contents; vigorous shaking of the container should be avoided.

Premarin solutions should be used immediately after reconstitution.Oral dosage preparations containing medroxyprogesterone acetate in combination with conjugated estrogens USP as monophasic or biphasic regimens are commercially available in a mnemonic dispensing package that is designed to aid the user in complying with the prescribed dosage schedule. The monophasic combination (Prempro) is available in a 28-day dosage preparation that contains 28 tablets of conjugated estrogens USP (0.625 mg) in fixed combination with medroxyprogesterone acetate (2.5 or 5 mg). The monophasic combination (Prempro) also is available in a 28-day dosage preparation that contains 28 tablets of conjugated estrogens USP (0.3 or 0.45 mg) in fixed combination with medroxyprogesterone acetate (1.5 mg). The biphasic combination (Premphase) is available in a 28-day dosage preparation that contains 14 tablets of conjugated estrogens USP (0.625 mg) and 14 tablets of conjugated estrogens USP (0.625 mg) in fixed combination with medroxyprogesterone acetate (5 mg).The oral dosage preparation containing conjugated estrogens in fixed combination with bazedoxifene acetate is commercially available in a 30-day package that includes 2 blister packs of 15 tablets each containing conjugated estrogens 0.45 mg in fixed combination with bazedoxifene acetate 22.6 mg (equivalent to 20 mg of bazedoxifene). DosageDosage of conjugated estrogens USP, synthetic conjugated estrogens A, and synthetic conjugated estrogens B must be individualized according to the condition being treated and the tolerance and therapeutic response of the patient.

To minimize the risk of adverse effects, the lowest possible effective dosage should be used. Because of the potential increased risk of cardiovascular events, breast cancer, and venous thromboembolic events, therapy with estrogen, estrogen/progestin, or conjugated estrogens in fixed combination with bazedoxifene should be limited to the lowest effective doses and shortest duration of therapy consistent with treatment goals and risks for the individual woman.

Therapy with estrogen, estrogen/progestin, or conjugated estrogens in fixed combination with bazedoxifene should be periodically reevaluated.Estrogen therapy is administered in a continuous daily dosage regimen or, alternatively, in a cyclic regimen. When estrogens are administered cyclically, the drugs usually are given once daily for 3 weeks followed by 1 week without the drugs or once daily for 25 days followed by 5 days off, and then the respective regimen is repeated as necessary.While estrogen therapy alone (estrogen replacement therapy, ERT) may be appropriate in women who have undergone a hysterectomy, a progestin generally is added to estrogen therapy (hormone replacement therapy, HRT) in women with an intact uterus. Addition of a progestin for 10 or more days of a cycle of estrogen or daily with estrogen in a continuous regimen reduces the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in women with an intact uterus.

Morphologic and biochemical studies of the endometrium suggest that 10-13 days of progestin are needed to provide maximum maturation of the endometrium and to eliminate any hyperplastic changes. As an alternative to progestins, the use of bazedoxifene (an estrogen agonist-antagonist) in fixed combination with conjugated estrogens reduces the risk of endometrial hyperplasia.When estrogen therapy is used in conjunction with a progestin or in fixed combination with bazedoxifene, the usual precautions associated with progestins or bazedoxifene should be observed.

Clinicians prescribing estrogens in conjunction with progestins or conjugated estrogens in fixed combination with bazedoxifene should be aware of the risks associated with these drugs and the manufacturers' labeling should be consulted. Clinical studies indicate that addition of a progestin to estrogen replacement therapy does not interfere with the efficacy of estrogen therapy in the management of vasomotor symptoms associated with menopause, treatment of vulvar and vaginal atrophy, or prevention of osteoporosis. The choice and dosage of a progestin may be important factors in minimizing potential adverse effects.Exposure to conjugated estrogens USP vaginal cream has been reported to weaken latex condoms. The potential for conjugated estrogens USP vaginal cream to weaken and contribute to the protective failure of latex or rubber condoms, diaphragms, or cervical caps should be considered. Menopausal Symptoms Conjugated Estrogens USPFor the management of moderate to severe vasomotor symptoms and/or for the management of vulvar and vaginal atrophy associated with menopause, the usual initial oral dosage of conjugated estrogens USP is 0.3 mg daily. Subsequent dosage adjustment should be based on the patient's response. The drug may be administered in a continuous daily regimen or in a cyclic regimen (25 days on drug followed by 5 days off drug, then this regimen is repeated as necessary).

This table provides a summary of the Weight or Mass units within their respective measurement systems.